UBS is painting a picture of a market that’s exhausted rather than panicked. The bank’s latest risk assessment describes a softer tone across equities, with long-only buyers pulling back while selling pressure, particularly in tech, becomes less aggressive. Quality names and financials are picking up the slack, providing a stabilizing effect that’s keeping the floor from falling out entirely.

What UBS is actually seeing

Long-only institutional buyers are stepping to the sidelines, removing a key source of buying pressure. But at the same time, the aggressive selling that hammered tech stocks has cooled. Quality stocks and financials are improving in relative terms.

The Philadelphia Semiconductor Index experienced a 10.3% drop before staging a rebound during the March-to-June window. The S&P 500 tracked similar turbulence during the same period, reflecting how deeply tech sentiment bleeds into broader market indices.

The playbook UBS is recommending

UBS has been advocating a shift away from energy-sensitive and cyclical sectors into growth and defensive areas. That recommendation was formalized around late March 2026, when the combination of higher interest rate expectations, valuation concerns, and geopolitical tensions created a cocktail that made cyclical exposure look increasingly risky.

Specifically, UBS upgraded Swiss equities and European health care in its March 24, 2026 recommendations, citing stable earnings, lower correlation to US monetary policy uncertainty, and attractive relative valuations compared to US tech.

By May 29, 2026, the tactical guidance had evolved further. UBS began recommending short-term derisking into bonds and structured products, even while maintaining that long-term equity positions remain attractive.